Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Abstract Background Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and has a high mortality rate worldwide. Sorafenib is the only systemic treatment demonstrating a statistically significant but modest overall survival benefit. We previously have identified the aurora kinases...

Full description

Bibliographic Details
Main Authors: You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Journal of Biomedical Science
Subjects:
Hepatocellular carcinoma
Multikinase inhibitors
Aurora kinases
Sorafenib resistance
Online Access:https://doi.org/10.1186/s12929-022-00788-0

Internet

https://doi.org/10.1186/s12929-022-00788-0

Similar Items